U.S. Markets close in 2 hrs 42 mins

Envisia Therapeutics To Present At American Glaucoma Society 2017 Annual Meeting

RESEARCH TRIANGLE PARK, N.C., March 2, 2017 /PRNewswire/ -- Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today announced that it will present a podium presentation and two posters at the American Glaucoma Society (AGS) Annual Meeting being held March 2-6, 2017 in San Diego, CA.

Precisely Engineering The Future Of Ophthalmology.

"We are honored to have the opportunity to present a comprehensive data set from our ENV515 glaucoma program and look forward to engaging in scientific exchange among our peers at the AGS Annual Meeting," said Benjamin Yerxa, PhD, President of Envisia Therapeutics. "The data that will be presented highlight the potential of our investigational ENV515 travoprost extended-release product to become a once-a-year therapy for intraocular pressure (IOP) control in glaucoma patients."

All Envisia presentations will take place on Friday, March 3; details are as follows:

Oral presentation PA09: Interim Analysis of Low Dose ENV515 Travoprost XR with 9 Month Duration and IOP-Lowering Effects of Pre-Study PGAs and In-Study Timolol    Ballroom, Hotel Del Coronado, Coronado, California, 8:41 AM
Presented by Dr. Steven L. Mansberger, MD, MPH – Devers Eye Institute

Poster Presentation PO097: Design and Development of ENV515 Intraocular Applicator Including Custom Needle for Intracameral Injections of ENV515 Travoprost Extended Release (XR) Therapy for Glaucoma
Coronet Room, Hotel Del Coronado, Coronado, California, 7:00am - 8:00am  
Presented by Akshay Nadkarni, MS, Senior Process Development Engineer, Envisia Therapeutics

Poster Presentation PO090: Changing the Paradigm of PGA Dosing in Glaucoma with Extended Release Formulations: Continuous PGA Release Results in Significant Drug Sparing Compared to Topical PGAs and Achieves Sustained IOP Lowering for 9 Months without Any Attenuation in IOP-lowering Effect 
Coronet Room, Hotel Del Coronado, Coronado, California, 7:00am - 8:00am 
Presented by Tomas Navratil, PhD, Senior Vice President, Development, Envisia Therapeutics

Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, extended-release formulation of a marketed prostaglandin analogue with the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. In January 2015, the company initiated a phase 2a clinical trial to investigate the safety and tolerability of ENV515 in patients with glaucoma.

Envisia is located in Research Triangle Park, North Carolina. For more information, please go to www.envisiatherapeutics.com.


To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/envisia-therapeutics-to-present-at-american-glaucoma-society-2017-annual-meeting-300417335.html